Posted by Michael Wonder on 05 Jun 2021
Newly approved obesity drug Wegovy holds promise, but faces reimbursement challenges
5 June 2021 - On 4 June, the FDA approved Novo Nordisk’s obesity drug Wegovy (semaglutide), a glucagon-like peptide 1 receptor agonist, to be injected subcutaneously once-weekly.
Wegovy is a higher dose - 2.4 mg version of the diabetes drug Ozempic (semaglutide).
Novo Nordisk hasn’t revealed Wegovy’s list price, but hinted that it will be similar to the price of its drug Saxenda, a weight loss treatment that retails at $1,300/month without insurance.
